How much revenue did BARD1 Life Sciences generate this year?
BARD1 Life Sciences has achieved a revenue of 510,980 AUD this year.
BARD1 Life Sciences Revenue 2024
BARD1 Life Sciences Revenue
510,980 AUD
Ticker
BD1.AX
ISIN
AU000000BD12
WKN
A2AL50
In 2024, BARD1 Life Sciences's sales reached 510,980 AUD, a 419.34% difference from the 98,390 AUD sales recorded in the previous year.
The BARD1 Life Sciences Revenue history
| YEAR | REVENUE (undefined AUD) | GROSS MARGIN (%) |
|---|---|---|
| 2021 | 0.51 | 87,47 |
| 2020 | 0.1 | 454,24 |
| 2019 | 0.01 | 5119,47 |
| 2018 | 0.01 | 6198,75 |
| 2017 | 0 | 10641,19 |
| 2016 | - | - |
| 2015 | - | - |
| 2014 | - | - |
| 2013 | 0.01 | 4469,30 |
| 2012 | 0.3 | 148,98 |
| 2011 | 0.2 | 223,46 |
| 2010 | 1.46 | 30,61 |
| 2009 | 6.93 | 6,45 |
| 2008 | 5.88 | 7,60 |
| 2007 | 0.03 | 1489,77 |
| 2006 | 0.19 | 47,37 |
| 2005 | 0.37 | 89,19 |
| 2004 | 0.63 | 84,13 |
| 2003 | 1.28 | 86,72 |
| 2002 | 2.25 | 84,89 |
BARD1 Life Sciences Revenue, EBIT, Net Income AU000000BD12 · A2AL50
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into BARD1 Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BARD1 Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BARD1 Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of BARD1 Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into BARD1 Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing BARD1 Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BARD1 Life Sciences’s growth potential.
BARD1 Life Sciences Revenue, EBIT and net profit per share
| Date | BARD1 Life Sciences Revenue | BARD1 Life Sciences EBIT | BARD1 Life Sciences Net Income |
|---|---|---|---|
| 2021 | 510,980 AUD | -6.59 M AUD | -11.15 M AUD |
| 2020 | 98,390 AUD | -2.33 M AUD | -3.25 M AUD |
| 2019 | 8,730 AUD | -1.77 M AUD | -1.72 M AUD |
| 2018 | 7,210 AUD | -1.92 M AUD | -1.82 M AUD |
| 2017 | 4,200 AUD | -2.59 M AUD | -2.6 M AUD |
| 2016 | 0 AUD | -130,000 AUD | -2.84 M AUD |
| 2015 | 0 AUD | 0 AUD | 0 AUD |
| 2014 | 0 AUD | 0 AUD | 0 AUD |
| 2013 | 10,000 AUD | -610,000 AUD | -10.52 M AUD |
| 2012 | 300,000 AUD | -590,000 AUD | -10.45 M AUD |
| 2011 | 200,000 AUD | -1.03 M AUD | -1.56 M AUD |
| 2010 | 1.46 M AUD | 480,000 AUD | -1.61 M AUD |
| 2009 | 6.93 M AUD | 5.78 M AUD | 3.76 M AUD |
| 2008 | 5.88 M AUD | 4.85 M AUD | 3.16 M AUD |
| 2007 | 30,000 AUD | 700,000 AUD | -11.09 M AUD |
| 2006 | 190,000 AUD | -3.52 M AUD | -10.22 M AUD |
| 2005 | 370,000 AUD | -2.27 M AUD | -3.13 M AUD |
| 2004 | 630,000 AUD | -690,000 AUD | -1.13 M AUD |
| 2003 | 1.28 M AUD | -580,000 AUD | -1.34 M AUD |
| 2002 | 2.25 M AUD | -30,000 AUD | -180,000 AUD |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2002 | 2.25 M AUD | -30,000 AUD | -180,000 AUD |
| 2003 | 1.28 M AUD | -580,000 AUD | -1.34 M AUD |
| 2004 | 630,000 AUD | -690,000 AUD | -1.13 M AUD |
| 2005 | 370,000 AUD | -2.27 M AUD | -3.13 M AUD |
| 2006 | 190,000 AUD | -3.52 M AUD | -10.22 M AUD |
| 2007 | 30,000 AUD | 700,000 AUD | -11.09 M AUD |
| 2008 | 5.88 M AUD | 4.85 M AUD | 3.16 M AUD |
| 2009 | 6.93 M AUD | 5.78 M AUD | 3.76 M AUD |
| 2010 | 1.46 M AUD | 480,000 AUD | -1.61 M AUD |
| 2011 | 200,000 AUD | -1.03 M AUD | -1.56 M AUD |
| 2012 | 300,000 AUD | -590,000 AUD | -10.45 M AUD |
| 2013 | 10,000 AUD | -610,000 AUD | -10.52 M AUD |
| 2014 | 0 AUD | 0 AUD | 0 AUD |
| 2015 | 0 AUD | 0 AUD | 0 AUD |
| 2016 | 0 AUD | -130,000 AUD | -2.84 M AUD |
| 2017 | 4,200 AUD | -2.59 M AUD | -2.6 M AUD |
| 2018 | 7,210 AUD | -1.92 M AUD | -1.82 M AUD |
| 2019 | 8,730 AUD | -1.77 M AUD | -1.72 M AUD |
| 2020 | 98,390 AUD | -2.33 M AUD | -3.25 M AUD |
| 2021 | 510,980 AUD | -6.59 M AUD | -11.15 M AUD |
BARD1 Life Sciences stock margins AU000000BD12 · A2AL50
The BARD1 Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BARD1 Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BARD1 Life Sciences.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the BARD1 Life Sciences's sales revenue. A higher gross margin percentage indicates that the BARD1 Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the BARD1 Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the BARD1 Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BARD1 Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BARD1 Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BARD1 Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
BARD1 Life Sciences Margin History
| BARD1 Life Sciences Gross margin | BARD1 Life Sciences Profit margin | BARD1 Life Sciences EBIT margin | BARD1 Life Sciences Profit margin |
|---|---|---|---|
| 2021 | 87.47 % | -1,290.51 % | -2,182.25 % |
| 2020 | 87.47 % | -2,370.73 % | -3,306.79 % |
| 2019 | 87.47 % | -20,305.96 % | -19,670.91 % |
| 2018 | 87.47 % | -26,624.55 % | -25,205.27 % |
| 2017 | 87.47 % | -61,721.43 % | -62,004.05 % |
| 2016 | 87.47 % | 0 % | 0 % |
| 2015 | 87.47 % | 0 % | 0 % |
| 2014 | 87.47 % | 0 % | 0 % |
| 2013 | 87.47 % | -6,100 % | -105,200.01 % |
| 2012 | 87.47 % | -196.67 % | -3,483.33 % |
| 2011 | 87.47 % | -515 % | -780 % |
| 2010 | 87.47 % | 32.88 % | -110.27 % |
| 2009 | 87.47 % | 83.41 % | 54.26 % |
| 2008 | 87.47 % | 82.48 % | 53.74 % |
| 2007 | 87.47 % | 2,333.33 % | -36,966.67 % |
| 2006 | 47.37 % | -1,852.63 % | -5,378.95 % |
| 2005 | 89.19 % | -613.51 % | -845.95 % |
| 2004 | 84.13 % | -109.52 % | -179.37 % |
| 2003 | 86.72 % | -45.31 % | -104.69 % |
| 2002 | 84.89 % | -1.33 % | -8 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2002 | 84.89 % | -1.33 % | -8 % |
| 2003 | 86.72 % | -45.31 % | -104.69 % |
| 2004 | 84.13 % | -109.52 % | -179.37 % |
| 2005 | 89.19 % | -613.51 % | -845.95 % |
| 2006 | 47.37 % | -1,852.63 % | -5,378.95 % |
| 2007 | 87.47 % | 2,333.33 % | -36,966.67 % |
| 2008 | 87.47 % | 82.48 % | 53.74 % |
| 2009 | 87.47 % | 83.41 % | 54.26 % |
| 2010 | 87.47 % | 32.88 % | -110.27 % |
| 2011 | 87.47 % | -515 % | -780 % |
| 2012 | 87.47 % | -196.67 % | -3,483.33 % |
| 2013 | 87.47 % | -6,100 % | -105,200.01 % |
| 2014 | 87.47 % | 0 % | 0 % |
| 2015 | 87.47 % | 0 % | 0 % |
| 2016 | 87.47 % | 0 % | 0 % |
| 2017 | 87.47 % | -61,721.43 % | -62,004.05 % |
| 2018 | 87.47 % | -26,624.55 % | -25,205.27 % |
| 2019 | 87.47 % | -20,305.96 % | -19,670.91 % |
| 2020 | 87.47 % | -2,370.73 % | -3,306.79 % |
| 2021 | 87.47 % | -1,290.51 % | -2,182.25 % |
BARD1 Life Sciences Aktienanalyse
What does BARD1 Life Sciences do?
BARD1 Life Sciences Ltd. is an Australian biotechnology company specializing in the development of diagnostics and therapeutics for cancer. The company was founded in 1999 and is headquartered in Sydney. BARD1 Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding BARD1 Life Sciences's Sales Figures
The sales figures of BARD1 Life Sciences originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing BARD1 Life Sciences’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize BARD1 Life Sciences's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in BARD1 Life Sciences’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about BARD1 Life Sciences stock
How much was the turnover of the company BARD1 Life Sciences compared to the previous year?
The revenue of BARD1 Life Sciences has increased by 419.34% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of BARD1 Life Sciences?
The revenue of BARD1 Life Sciences is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of BARD1 Life Sciences measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of BARD1 Life Sciences so important for investors?
The revenue of BARD1 Life Sciences is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does BARD1 Life Sciences pay?
Over the past 12 months, BARD1 Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BARD1 Life Sciences is expected to pay a dividend of 0 AUD.
What is the dividend yield of BARD1 Life Sciences?
The current dividend yield of BARD1 Life Sciences is .
When does BARD1 Life Sciences pay dividends?
BARD1 Life Sciences pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BARD1 Life Sciences?
BARD1 Life Sciences paid dividends every year for the past 0 years.
What is the dividend of BARD1 Life Sciences?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is BARD1 Life Sciences located?
BARD1 Life Sciences is assigned to the 'Health' sector.
Wann musste ich die Aktien von BARD1 Life Sciences kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BARD1 Life Sciences from 11/3/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.
When did BARD1 Life Sciences pay the last dividend?
The last dividend was paid out on 11/3/2024.
What was the dividend of BARD1 Life Sciences in the year 2023?
In the year 2023, BARD1 Life Sciences distributed 0 AUD as dividends.
In which currency does BARD1 Life Sciences pay out the dividend?
The dividends of BARD1 Life Sciences are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von BARD1 Life Sciences
Our stock analysis for BARD1 Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BARD1 Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- BARD1 Life Sciences Revenue
- BARD1 Life Sciences Net Income
- BARD1 Life Sciences P/E
- BARD1 Life Sciences P/S
- BARD1 Life Sciences EBIT
- BARD1 Life Sciences Dividend
- BARD1 Life Sciences Stocks
- BARD1 Life Sciences Market capitalization
- BARD1 Life Sciences Debt
- BARD1 Life Sciences Liabilities
- BARD1 Life Sciences Equity
- BARD1 Life Sciences AAQS
- BARD1 Life Sciences Employees
- BARD1 Life Sciences ROE
- BARD1 Life Sciences ROA
- BARD1 Life Sciences ROCE
